This report describes a nanobody targeting glycine receptor mGlyR that inhibits its ability to regulate G protein signaling and produces anti-depressant effects in mice providing an immunotherapy approach to potentially treat depression.
- Thibaut Laboute
- Stefano Zucca
- Kirill A. Martemyanov